Please login to the form below

Not currently logged in
Email:
Password:

Adaptimmune appoints Lawrence Alleva to its board

The former PwC partner will also chair its boardaudit committee

Adaptimmune Lawrence Larry Alleva Adaptimmune has appointed former PwC partner Lawrence (Larry) Alleva to its board of directors as an independent, non-executive director.

Alleva will also serve as chairman of the Oxford, UK-based clinical-stage biotechnology company's board audit committee.

Commenting on his new role he said: “I am very pleased to be joining Adaptimmune at this interesting time, and I look forward to working closely with the team as we aim to build the company up with the expansion of its UK and US operations.”

Alleva spent 39 years with PricewaterhouseCoopers (PwC), until his retirement in 2010, and served in a variety of office, regional and national practice leadership roles, most recently as the US ethics and compliance leader for the firm's Assurance Practice from 2006.

He currently serves as a director for public companies Tesaro and Bright Horizons Family Solutions, and for the privately-held Mirna Therapeutics, and chairs those companies' audit committees.

Dr Jonathan Knowles, chairman of Adaptimmune, said: “I am delighted that such a high caliber individual as Larry Alleva has agreed to join our board of directors.

"His substantial corporate finance and accounting expertise, combined with his extensive experience of supporting growing biotech firms, brings significant added value to the company, and complements the skills and experience of our other board members.”

Alleva's appointment follows a brace of recent senior hires that saw Adaptimmune recruit a new chief medical officer and chief financial officer.

11th March 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics